Abstract

For almost 30 years, researchers have investigated the impact of oxidation of first low-density lipoproteins (LDLs) and then of high-density lipoproteins (HDLs) in pathology. The involvement of myeloperoxidase (MPO) in the oxidation process of these lipoproteins has appeared to play a key role in cardiovascular disease (CVD), such as atherosclerosis. Indeed, it is now confirmed that MPO adsorbs on lipoproteins and specifically modifies them, generating pro-atherogenic lipoproteins commonly named Mox-LDLs and Mox-HDLs. In this chapter, the role of MPO in the contribution to modifications of LDLs and HDLs is discussed as well as its roles in cardiovascular disease development linked to oxidized lipoproteins.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.